Moderna, Covid-19

Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.
Moderna Stock Jumps on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed its full-year sales forecast. Covid vaccine sales totaled $1.8 billion for the third quarter.
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday note to investors said sales of the company’s respiratory syncytial virus vaccine mRESVIA was significantly lower than expected.
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,
Moderna Turns To Profit In Q3; Backs FY24 Net Product Sales View; Stock Up
Drug maker Moderna, Inc. (MRNA) reported Thursday that its third-quarter net income was $13 million, compared to a net loss of $3.63
Moderna Stock Rises on Surprise Q3 Profit
Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of its updated COVID vaccine.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
Moderna’s stock pops after biotech ekes out profit and revenue beats by a wide margin
Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...
BioPharma Dive4h
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Moderna EPS Beats Estimates, Sales Rise
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Detroit News5h
Moderna sales get lift from early nod for newest COVID shot
Moderna Inc. delivered better-than-expected profit and sales in the third quarter after an early start to sales of this ...
Moderna CEO Bancel steps down as sales chief, Bloomberg News reports
Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...
Moderna’s Bancel steps down as sales chief, keeps CEO role
Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date ...
Moderna (MRNA) Q3 2024 Earnings Call Transcript
Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...